Register for free to
view the full innovation profile.
MicroRNA96 reduces pulmonary vascular remodelling, pulmonary arterial pressures, right ventricular hypertrophy and increases right ventricular function.
About
Scientists at Strathclyde have demonstrated effectiveness of microRNA96, delivered to the lung, in a model of severe pulmonary hypertension. MicroRNA96 reduces pulmonary vascular remodelling, pulmonary arterial pressures, right ventricular hypertrophy and increases right ventricular function. MicroRNA96 is a non-coding RNA that targets the gene for the 5HT1B receptor, decreasing its expression. The 5HT1B receptor mediates the pathogenic effects of serotonin in the human pulmonary artery. Serotonin mediates many pathogenic effects in the human pulmonary circulation and these are exaggerated in pulmonary hypertension. Many of these effects are mediated by the 5HT1B receptor in man. Unlike other potential approaches, when delivered locally, the effects of microRNA96 are specific to the lung and do not affect other serotonin-mediated systems.
Key Benefits
· Inhibition of vascular cell proliferation and vascular remodelling · Effects are lung specific · Patented technology
Applications
For the treatment of Pulmonary Arterial Hypertension (PAH) and other medical conditions requiring Inhibition of vascular cell proliferation and/or vascular remodelling